Exogenous surfactant delivery is therefore considered to hold potential for ARDS treatment, but clinical trials with natural derived surfactant or synthetic surfactant containing a surfactant protein C (SP‐C) analogue have been negative. Here, SFTPC is linked to acute respiratory distress syndrome.